drugset / Trial / NCT02639078

Single Ascending Dose Study of TD-0714 in Healthy Subjects

NCT02639078 ↗

Phase 1 Completed 56 enrolled Theravance Biopharma
RandomizedParallel-groupDouble-blindBasic science

Summary

Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-0714 in healthy subjects.

Timeline

Start
2015-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TD-0714 Unknown — —

Indications

No indication recorded.